BioSpace News Archive

Seegene Inc. announced on November 10 that it has received an overall rating of ‘B+' in the 2023 ESG evaluation conducted by the Korea Institute of Corporate Governance and Sustainability.

Madrigal Pharmaceuticals, Inc. today announced that Carole Huntsman has been appointed Chief Commercial Officer.

JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; “JCR”) announced today that the first patient in the Phase I/II clinical trial with Mucopolysaccharidosis Type IIIA (MPS IIIA; Sanfilippo Syndrome Type A) has been dosed with JR‑441, a blood-brain barrier (BBB) penetrating form of heparan N-sulfatase that was developed using JCR’s proprietary J-Brain Cargo ® BBB-penetrating technology.

Aligos Therapeutics, Inc. announced that emerging hepatitis B antigen lowering data for its capsid assembly modulator – empty drug, ALG-000184, are available as a late breaking poster at The Liver Meeting® of the American Association for the Study of Liver Diseases, being held in Boston, Massachusetts, November 10 – 14, 2023.

Merck Receives Positive EU CHMP Opinion for KEYTRUDA ® (pembrolizumab) Plus Gemcitabine and Cisplatin as First-Line Treatment for Locally Advanced Unresectable or Metastatic Biliary Tract Cancer.

Ventyx Biosciences, Inc. announced that Company executives will participate in the upcoming Jefferies London Healthcare Conference.

Roivant announced the appointment of Mayukh Sukhatme, M.D., to its Board of Directors, effective immediately.

IO Biotech (Nasdaq: IOBT) announced today that it has completed enrollment in the pivotal Phase 3 clinical trial for IO102-IO103, in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with advanced melanoma.

Lipella Pharmaceuticals Inc. announced today that it has been granted “Orphan Drug Designation” from the U.S. Food and Drug Administration (FDA) for its drug candidate, LP-310, which has been designed for the treatment of oral Graft-versus-Host Disease (GvHD).

Sosei Group Corporation announced the successful identification, validation and nomination of a first G protein-coupled receptor target to enter a therapeutic discovery program for gastrointestinal diseases.